Subscribe
pavel-kapysh-lundbeck
Pavel Kapysh / Shutterstock.com
30 March 2021EuropeAlex Baldwin

Lundbeck loses €150m pay-for-delay appeal

Lundbeck has lost an appeal to the  Court of Justice of the European Union (CJEU) to waive €150 million ($176 million) in fines levied against itself and a group of five generics manufacturers over ‘pay-for-delay’ deals for its antidepressant generics.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Why the ‘first penguin’ of pay for delay has not come in Japan: anatomy of a Japan paradox
27 May 2022   Why does Japan have no reverse payments culture? Takanori Abe of Abe & Partners unpicks a complex issue.
Big Pharma
AG advises CJEU to uphold €94 million pay-for-delay fine
5 June 2020   The advocate general has recommended that the Court of Justice of the European Union uphold an almost €94 million fine imposed on Lundbeck for its pay-for-delay scheme.
Big Pharma
EU General Court backs Lundbeck fine in pay-for-delay case
12 September 2016   The EU General Court has backed the European Commission’s decision to fine pharma company Lundbeck and a number of generic producers.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Generics
Why the ‘first penguin’ of pay for delay has not come in Japan: anatomy of a Japan paradox
27 May 2022   Why does Japan have no reverse payments culture? Takanori Abe of Abe & Partners unpicks a complex issue.
Big Pharma
AG advises CJEU to uphold €94 million pay-for-delay fine
5 June 2020   The advocate general has recommended that the Court of Justice of the European Union uphold an almost €94 million fine imposed on Lundbeck for its pay-for-delay scheme.
Big Pharma
EU General Court backs Lundbeck fine in pay-for-delay case
12 September 2016   The EU General Court has backed the European Commission’s decision to fine pharma company Lundbeck and a number of generic producers.

More on this story

Generics
Why the ‘first penguin’ of pay for delay has not come in Japan: anatomy of a Japan paradox
27 May 2022   Why does Japan have no reverse payments culture? Takanori Abe of Abe & Partners unpicks a complex issue.
Big Pharma
AG advises CJEU to uphold €94 million pay-for-delay fine
5 June 2020   The advocate general has recommended that the Court of Justice of the European Union uphold an almost €94 million fine imposed on Lundbeck for its pay-for-delay scheme.
Big Pharma
EU General Court backs Lundbeck fine in pay-for-delay case
12 September 2016   The EU General Court has backed the European Commission’s decision to fine pharma company Lundbeck and a number of generic producers.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB